Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - adhoc news (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1958515
31 July 2024 06:36PM

CompuGroup Medical SE & Co. KGaA appoints Prof. Dr. Daniel Gotthardt as new CEO


EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Personnel
CompuGroup Medical SE & Co. KGaA appoints Prof. Dr. Daniel Gotthardt as new CEO

31-Jul-2024 / 18:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical SE & Co. KGaA appoints Prof. Dr. Daniel Gotthardt as new CEO

Koblenz, Germany. The general partner of CompuGroup Medical SE & Co. KGaA (the “Company”) (ISIN: DE000A288904 | WKN: A28890) announces that the Administrative Board of CompuGroup Medical Management SE and CEO Michael Rauch decided today in mutual agreement to terminate his contract prematurely as of August 31, 2024, including resignation from his position as Managing Director and member of the Administrative Board of CompuGroup Medical Management SE as well as of the Joint Committee of the Company.

Effective as of September 1, 2024, the Administrative Board of CompuGroup Medical Management SE appoints Prof. (apl.) Dr. med. Daniel Gotthardt as Managing Director and CEO. Daniel Gotthardt has been Senior Vice President and Chief Medical Officer of the Company since the beginning of 2023. He has also been a member of the Supervisory Board of former CompuGROUP Holding AG and CompuGroup Medical SE since 2003, and has been a member of the Administrative Board of CompuGroup Medical Management SE since 2020.

 

 

 



End of Inside Information

31-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1958515

 
End of Announcement EQS News Service

1958515  31-Jul-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1958515&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.